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Despite the promising therapeutic effects of immune checkpoint blockade (ICB),
most patients with solid tumors treated with anti-PD-1/PD-L1 monotherapy do not
achieve objective responses, with most tumor regressions being partial rather than
complete. It is hypothesized that the absence of pre-existing antitumor immunity
and/or the presence of additional tumor immune suppressive factors at the tumor
microenvironment are responsible for such therapeutic failures. It is therefore clear
that in order to fully exploit the potential of PD-1 blockade therapy, antitumor
immune response should be amplified, while tumor immune suppression should be
further attenuated. Cancer vaccines may prime patients for treatments with ICB by
inducing effective anti-tumor immunity, especially in patients lacking tumor-infiltrating
T-cells. These “non-inflamed” non-permissive tumors that are resistant to ICB could
be rendered sensitive and transformed into “inflamed” tumor by vaccination. In this
article we describe a clinical study where we use pancreatic cancer as a model,
and we hypothesize that effective vaccination in pancreatic cancer patients, along
with interventions that can reprogram important immunosuppressive factors in the
tumor microenvironment, can enhance tumor immune recognition, thus enhancing
response to PD-1/PD-L1 blockade. We incorporate into the schedule of standard of
care (SOC) chemotherapy adjuvant setting a vaccine platform comprised of autologous
dendritic cells loaded with personalized neoantigen peptides (PEP-DC) identified
through our own proteo-genomics antigen discovery pipeline. Furthermore, we add
nivolumab, an antibody against PD-1, to boost and maintain the vaccine’s effect.
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We also demonstrate the feasibility of identifying personalized neoantigens in three
pancreatic ductal adenocarcinoma (PDAC) patients, and we describe their optimal
incorporation into long peptides for manufacturing into vaccine products. We finally
discuss the advantages as well as the scientific and logistic challenges of such an
exploratory vaccine clinical trial, and we highlight its novelty.
Keywords: pancreatic adenocarcinoma, dendritic cell vaccine, antigen discovery, neoantigen, cancer
immunotherapy
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading
cause of cancer-related death in the world in 2018 (1), with
an overall 5-year survival rate of ∼5% (2). Approximately 70%
of deaths are due to widespread metastasis and the remaining
cases have limited metastasis but extensive primary tumors
which eventually lead to mortality (3). Surgery is the only
potential hope of cure for PDAC, but tumors are resectable
only in 20% of patients at the time of diagnosis. Therapeutic
research efforts have mainly focused on improvements in
radio/chemo treatments and to date, there are only a few
chemotherapeutic agents that have shown to be effective against
advanced pancreatic cancer, including gemcitabine with or
without abraxane (4). At present, it is difficult to conclude that
there is a definite SOC adjuvant chemotherapy for all patients
with PDAC. However, multiagent adjuvant therapy (modified
folforinox) has been demonstrated to be more effective than
gemcitabine alone in the adjuvant setting, but its use is limited
only to patients with excellent performance status (5). Recently it
has suggested that gemcitabine plus capecitabine is a valid option
for these patients since it has been shown that it is more efficient
than gemcitabine alone (6).
One of the most promising new cancer treatment approaches
is immunotherapy. Recent studies have shown that PDAC
is an immunogenic tumor. Antigens expressed on pancreatic
tumor cells able to induce specific B and T cells comprise
(7): Wilms’ tumor gene 1 (WT1) (75%) (8), mucin 1 (MUC1)
(over 85%) (9), human telomerase reverse transcriptase (hTERT)
(88%) (10), mutated K-RAS (nearly 100%), survivin (77%),
carcinoembryonic antigen (CEA) (over 90%) (11), HER-
2/neu (over 60%) (12), p53 (over 65%) (13), and α-enolase
(ENO1) (14). Several studies have reported that dysfunction
of the immune system is one of the key contributors for
the development of PDAC (15, 16). Moreover, PDAC is
known to have an immunosuppressive tumor microenvironment
characterized by (i) the absence of intratumoral effector T-cells
(17, 18), (ii) the presence of an inflammatory tumor micro-
environment led by the RAS oncogene (19), and (iii) massive
infiltration of immunosuppressive leukocytes into the tumor
microenvironment, which predicts poor survival (18, 20, 21).
Additionally, the analysis of immune infiltrates in human tumors
has demonstrated a positive correlation between prognosis and
the presence of humoral response to pancreatic antigens (MUC-
1 andmesothelin) (22, 23) or of tumor-infiltrating T cells (20, 24).
Therefore, cancer immunotherapy can be a promising alternative
treatment for PDAC patients.
A major mechanism of immune resistance engaged by tumors
is the enforcement of immune checkpoint pathways, aiming to
shutdown T cells specific for tumor antigens. An important
immune checkpoint is mediated by the programmed cell death
protein 1 (PD-1) expressed on the surface of activated T cells
during initial activation (25, 26). The major role of PD-1 is
to limit the activity of T cells in peripheral tissues at the
time of an inflammatory response to infection and to restrict
autoimmunity (27, 28). Cancer immunotherapy targeting anti-
PD-1 (e.g., nivolumab, pembrolizumab), as well as anti-cytotoxic
T-lymphocyte-associated antigen 4 (anti-CTLA-4, ipilimumab),
has changed the treatment landscape of several tumors (29). Yet
the success of immunotherapy has not been proven effective
for the treatment of metastatic pancreatic cancer patients (30),
who have been shown unresponsive except for the population
withmismatch-repair deficiency which comprises only 0.8% (31).
A broad array of clinical trials in pancreatic cancer have been
completed or are ongoing using different combinations with ICB
(32, 33). However, the most adequate combination for PDAC
patients is not clear so far.
Dendritic cell (DC)-based vaccines for cancer
immunotherapy have been studied and tested for more
than a decade and proven clinically safe and efficient to induce
tumor-specific immune responses, however only limited efficacy
was observed in patients with advanced recurrent disease after
DC vaccination (34, 35). Several groups have attempted to test
safety and efficacy of DC-based vaccines against pancreatic
cancer in early phase clinical trials, loading DCs with tumor
associated antigens (TAAs) ex vivo, and subsequently re-infusing
them in patients, yet with low clinical benefit so far (36–39).
One possible reason for reduced vaccine efficacy could be that
most cancer vaccines tested to date were targeted against defined
non-mutated self-antigens. Tumors express two major kinds
of antigens that can be recognized by T cells: non-mutated
self-antigens and mutated neoantigens, generated in tumor
cells due to their inherent genetic instability (40). Tumor cells
usually harbor between 10 and few thousands private somatic
mutations, as identified by deep sequencing analysis, and even
among tumors of the same histotype, most mutations are
different (41, 42). Thus, neoantigens are mostly “private” and
patient-specific (43) and trigger a higher more robust T-cell
response. Indeed, increasing evidence associates clinical benefit
from immunotherapy with specific responses to private tumor
epitopes (44–48), leading to increased interest in neoantigen
vaccination (40).
Several clinical trials describing vaccines designed to harness
neoantigen-specific immunity have been recently reported
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mainly in melanoma patients: The first study reported the
feasibility, safety and efficacy of a DC vaccine pulsed with
neoantigen peptides (49). Another phase I study has evaluated
a peptide vaccine targeting up to 20 predicted personal tumor
neoantigens and demonstrated an expansion of the repertoire
of neoantigen-specific T cells which correlated with clinical
benefit (50). A second group performed a phase I study
using RNA vaccines that contained up to 10 mutations per
patient and demonstrated that these vaccines can mobilize
specific anti-tumor immunity against these cancers (51). These
studies provide proof-of-principle that a personalized vaccine
can be produced and administered to a patient to generate
highly specific immune responses against that individual’s tumor,
showing that a personalized neoantigen vaccine broadens the
repertoire of neoantigen-specific T cells substantially beyond
what is induced by existing immunotherapeutics.
To determine whether targetable mutations and neoantigens
exist in PDAC, several studies have been performed using
genomic profiles of PDAC tumor samples. A whole-genome
sequencing and copy number variation (CNV) analysis was
performed on 100 pancreatic ductal adenocarcinomas (PDACs)
and found in total 11,868 somatic structural variants at an
average of 119 per individual (range 15–558) (52). Furthermore,
the genomic profile of 221 PDAC tumors were analyzed and
the findings revealed that nearly all PDAC samples harbor
potentially targetable neoantigens (53). To define the importance
of neoantigens in PDAC, one study compared stage-matched
cohorts of treatment-naive, surgically resected, rare long-term
survivors to short-term survivors with a more typical poor
outcome. The authors detected a median of 38 predicted
neoantigens per tumor, and showed that the association of higher
neoantigen quantity and CD8+ T-cell infiltrate with survival
was independent of adjuvant chemotherapy, suggesting that
neoantigen quality, and not purely quantity, correlates with
survival (54).
We hypothesize that effective vaccination in PDAC patients
along with interventions that can reprogram important
immunosuppressive factors in the tumor microenvironment can
enhance tumor immune recognition, thus enhancing response
to PD-1/PD-L1 blockade. To this end, we designed a phase 1b
trial where we incorporated a vaccination schedule of a novel
autologous DC pulsed with personalized neoantigen peptides
(PEP-DC) identified through our own proteo-genomics antigen
discovery pipeline in the SOC chemotherapy adjuvant setting
followed by nivolumab. We hereby set the objectives and design
of our study, and we demonstrate the feasibility of identifying
personalized neoantigens in three PDAC patients, and their
optimal incorporation into long peptides for manufacturing into
vaccine products.
MATERIALS AND METHODS
Clinical Study Design
This is a phase Ib trial (CHUV-DO-0017_PC-PEPDC_2017) to
evaluate the feasibility, safety, immunogenicity, and efficacy
of subcutaneous DC vaccine loaded with personalized
peptides (PEP-DC), in combination with SOC chemotherapy
(gemcitabine/capecitabine) and enteric-coated aspirin, followed
by the anti-PD-1 antibody nivolumab to boost and maintain
the vaccine’s effect in patients with surgically resected PDAC.
The components of the vaccine to be investigated in this study
include agents for which safety has been previously demonstrated
to be acceptable. This trial has been approved by Swissmedic
and the competent Ethics Committee. Before any study-specific
procedure is performed, a signed and dated informed consent
is obtained. In order to be eligible, patients must present:
(a) histologically confirmed resected adenocarcinoma of the
pancreas (T1–T4, N 0–1, minimum 2 cm–AJCC 8th ed.) and
(b) appropriate amount of tumoral tissue collected from the
cytoreductive surgery, allowing the identification of top 10
personalized peptides (PEP) for preparation of PEP-DC vaccine.
Objectives
The primary objectives of the trial are to determine: (1) the
feasibility of producing and administering PEP-DC vaccine in
the indicated patient population; (2) the safety and tolerability
of the study treatment vaccine and aspirin given together
with SOC chemotherapy, and followed by nivolumab; (3)
the immunogenicity by measuring acquired T cell mediated
immune activation events post vaccination. This study has also
a secondary objective, which is to evaluate relapse free survival at
6, 12, 18, 24, and 36 months and overall survival in the indicated
population of patients.
Statistical Methods
We hypothesize that the delivery of the PEP-DC vaccine
through the subcutaneous route in combination with aspirin,
nivolumab, and adjuvant chemotherapy in advanced pancreatic
cancer patients is feasible, safe without additional toxicity, and
immunogenic. Based on study feasibility and anticipated accrual
rate, a total of 12 evaluable patients is expected to enter this
Phase Ib study if treatment limiting toxicities (TLTs) are in the
acceptable range.
The feasibility hypothesis for PEP-DC vaccine will be assessed
by (a) the number of patients in which vaccine production is
successful (at least 6 doses are manufactured and released), and
(b) the number of patients who receive at least one dose of
PEP-DC vaccine (since the mainstay of the therapeutic approach
here is PEP-DC) and the corresponding percentages in the
ITT population (i.e., all registered patients). Exact binomial
confidence intervals for the corresponding rates will be estimated.
The safety and tolerability of the PEP-DC vaccine in
combination with other protocol drugs will be evaluated by the
occurrence of TLTs and adverse events (AEs) in both the “TLT
evaluation” and the safety population. The severity of toxicities
will be classified according to the NCI CTCAE Version 4.03 and
will be presented in tabular as well as graphical format. For each
patient, each AEwill be presented considering the highest (worst)
grade of toxicity observed over the whole treatment period
according to CTCAE version 4.03. Although the safety of the
vaccination backbone has been already established, a continuous
monitoring rule will be followed, to allow for early termination of
the study. Any patient who receives at least one vaccination will
be included in the toxicity (safety) analysis. A Bayesian rule will
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be employed to monitor TLTs after groups of 4 patients have been
treated and complete the final TLT evaluation.
As only 5 weeks are allocated for target prioritization,
assessment of pre-vaccination immune responses against the
predicted neoantigens will not be performed to assist their
selection. Therefore, the selection of long peptides is done in
silico by the NeoDisc pipeline. The immunogenicity of PEP-
DC vaccine will be assessed (based on ITT population as
well as the safety population) by measuring acquired, T cell-
mediated immune activating events post vaccination compared
to pre-vaccination levels. Descriptive statistics of absolute and
relative differences will be calculated overall and for subgroups
of interest.
Regimen
The study was designed so that eligible subjects with PDAC
who undertook cytoreductive surgery followed by chemotherapy
may plan to enroll in the vaccine study. Should the subject
wishes, and upon informed consent, tissue can be harvested
at the time of surgery for identification of personalized targets
for vaccination. Screening of patients may be completed after
the collection of tumor was performed during the surgery.
Upon registration for the trial, all patients would receive 8
cycles of 21 day cycle of gemcitabine/capecitabine. Eligible
patients will undergo apheresis during the last week of the third
cycle of gemcitabine/capecitabine to collect peripheral blood
mononuclear cells for DC vaccine production. Patients will
receive at least six PEP-DC vaccinations starting concomitant
with the 5th cycle of chemotherapy. PEP-DC vaccine of 5–10 ×
106 autologous DC in 1ml volume/treatment will be delivered
subcutaneously every 3 weeks. Patients will receive oral enteric-
coated aspirin daily for the duration of the study starting from the
day of first vaccination until the end of study. Nivolumab will be
administered starting 3 weeks after last chemotherapy cycle and
will be given during the vaccination period until the last vaccine
dose. Afterwards, it will be given as a maintenance therapy
until appearance of new lesion(s) or unacceptable toxicity for
maximum 2 years.
To verify that the combination of PEP-DC vaccine and
enteric-coated aspirin during and following standard adjuvant
chemotherapy, followed by nivolumab, will significantly
enhance tumor immunogenicity, and allow tumor response,
the translational objectives of the study are the following: (a) to
deeply characterize the tumor microenvironment of pancreatic
adenocarcinoma patients; (b) to assess the overall effects of
the combined PEP-DC vaccine during and following standard
adjuvant chemotherapy, followed by nivolumab on peripheral
blood and plasma; (c) to determine tumor antigens against which
the treatment elicits a response.
Identification of Personalized Targets for
Vaccination With NeoDisc
Processing of Patients’ Material for PEP-DC Vaccine
Preparation
Informed consent of the participants was obtained
following requirements of the institutional review board
(Ethics Commission, CHUV). The translational research
has been approved by the CHUV ethics committee
(protocols 2017-00305).
DNA Extraction and Sequencing
DNA was extracted for HLA typing and exome sequencing
with the commercially available DNeasy Blood & Tissue
Kit (Qiagen, Hilden, Germany), following manufacturers’
protocols. Five hundred nanograms of gDNA were used to
amplify HLA genes by PCR. High resolution 4-digit HLA
typing was performed with the TruSight HLA v2 Sequencing
Panel from Illumina on a MiniSeq instrument (Illumina)
(Supplementary Table 1). Sequencing data were analyzed with
the Assign TruSight HLA v2.1 software (Illumina). For exome
sequencing, SureSelect Exome V5 library type (Sureselect v5
capture, Agilent Technologies, Santa Clara, CA, USA), and paired
end reads were chosen, with at least 100x coverage for the tumor
and PBMCs.
LC-MS/MS Analyses of Eluted HLA Peptides
For immunoaffinity purification of HLA peptides from tissues,
we applied a previously published protocol (55, 56). Briefly, anti-
HLA-I and anti-HLA-II monoclonal antibodies were purified
from the supernatant of HB95 (ATCC R© HB-95TM) and HB145
cells (ATCC R© HB-145TM) using protein-A sepharose 4B beads
(Invitrogen, Carlsbad, California), and cross-linked to the beads.
Snap-frozen PDAC tissue samples were homogenized in lysis
buffer on ice in 3–5 short intervals of 5 s each using an Ultra
Turrax homogenizer (IKA, T10 standard, Staufen, Germany)
at maximum speed, as previously described (55, 56). Lysates
were cleared by centrifugation at 25,000 rpm (Beckman Coulter,
JSS15314, Nyon, Switzerland) at 4◦C for 50min. The Waters
Positive Pressure-96 Processor (Waters, Milford, Massachusetts)
was used with 96-well, 3µm glass fiber and 10µm polypropylene
membranes micro-plates (Seahorse Bioscience, North Billerica,
Massachusetts). A depletion step of endogenous antibodies was
performed with plates containing Protein-A beads, and then
the lysates were passed through a plate containing beads cross-
linked to anti-HLA-I, and then sequentially through a plate with
the anti-HLA-II cross-linked beads. After washing with varying
concentrations of salts, the beads were washed twice 2mL of
20mM Tris-HCl pH 8. HLA complexes and the bound peptides
were eluted directly into pre-conditioned Sep-Pak tC18 100mg
plates (ref number: 186002321, Waters) with 1% TFA. After
washing the C18 wells with 2mL of 0.1% TFA, HLA-I peptides
were eluted with 28% ACN in 0.1% TFA, and HLA-II peptides
were eluted from the class II C18 plate with 500 µL of 32% ACN
in 0.1% TFA. HLA-I, and HLA-II peptide samples were dried
using vacuum centrifugation (Concentrator plus Eppendorf) and
stored at−20◦C.
We measured the peptides with LC-MS/MS system consisting
of an Easy-nLC 1200 (Thermo Fisher Scientific, Bremen,
Germany) and the Q Exactive HF-X mass spectrometer (Thermo
Fisher Scientific, Bremen, Germany). Peptides were separated on
a 450mm analytical column of 75µm inner diameter for 120min
using a gradient of H2O/FA 99.9/0.1% (A) and ACN/FA 80/0.1%
(B). The gradient was run as follows: 0min 2% B, then to 5% B at
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5min, 35% B at 85min, 60% B at 100min, and 95% B at 105min
at a flow rate of 250 nL/min.
MS spectra were acquired in the Orbitrap from m/z = 300–
1,650 with a resolution of 60,000 (m/z = 200), ion accumulation
time of 80ms. The AGC was set to 3e6 ions. MS/MS spectra were
acquired in a data-dependent manner, and 10 most abundant
precursor ions were selected for fragmentation, with a resolution
of 15,000 (m/z = 200), ion accumulation time of 120ms and
an isolation window of 1.2 m/z. The AGC was set to 2e5 ions,
dynamic exclusion to 20 s, and a normalized collision energy
(NCE) of 27 was used for fragmentation.
NeoDisc Pipeline
Alignment
Exome sequence reads were aligned to the Genome Reference
Consortium Human Build 37 assembly (GRCh37) with
BWA-MEM version 0.7.17 (57). The resulting SAM format
was sorted by chromosomal coordinate and converted into
a BAM file, then PCR duplicates were flagged, using the
Picard AddOrReplaceReadGroups and MarkDuplicates
utilities, respectively (from http://broadinstitute.github.io/
picard). Various quality metrics were assessed with the Picard
MarkDuplicates, CollectAlignmentSummaryMetrics, and
CalculateHsMetrics utilities. Following GATK best practices,
GATK BaseRecalibrator (within GATK v3.7-0) was used to
recalibrate base quality scores (BSQR) prior to variant calling
(58, 59). BQSR corrects base quality scores based on an
estimation of empirical error frequencies in the alignments. The
recalibrated tumor and germline BAM files were then used as
input for each of three variant callers: GATK HaplotypeCaller;
MuTect v1; and VarScan 2.
Caller 1: GATK HaplotypeCaller
The GATK HaplotypeCaller algorithm improves variant calling
by incorporating de-novo assembly of haplotypes in variable
regions, thus reducing the overall false-positive variant call rate
(58, 59). HaplotypeCaller was run in GVCF mode on each tumor
and germline recalibrated BAM file to detect SNV and Indel
variants. The resultant gVCF files were combined using GATK
GenotypeGVCF to produce raw variant calls for tumor and
germline within in a single VCF. Subsequent variant quality score
recalibration, following GATK best practices, was performed
separately for SNVs and Indels (insertions/deletions) using the
GATK variant Recalibrator tool to identify high-confidence calls.
Variant quality was assessed by the GATK VariantEval tool.
Patient-specific SNPs were defined as variants present in both
tumor and germline, while variants present only in tumor were
defined as somatic mutations.
Caller2: MuTect v1
TheMuTect variant calling algorithm predicts somaticmutations
based on log odds scores of two Bayesian classifiers (from https://
github.com/broadinstitute/mutect). The first classifier identifies
non-reference variants in the tumor sample while the second
detects whether those variants are tumor specific. Candidate
somatic mutations are then filtered based on read support, for
example by ensuring that supporting reads map to both DNA
strands, in order to reduce next-generation sequencing artifacts.
Identified somatic mutations are exported in VCF format.
Caller3: VarScan 2
The VarScan2 algorithm, unlike GATK and MuTect, relies on
hard filtering of calls rather than Bayesian statistics (60). This
has the advantage of being less sensitive to bias such as extreme
read coverage and sample contamination. VarScan 2 filters reads
based on parameters such as read quality, strand bias, minimum
coverage, and variant frequency. The multisample pileup file
required for VarScan 2 input was generated with SAMtools (61,
62). VarScan 2 was run using default parameters and generated
a VCF containing SNVs and Indels for both somatic mutations
and SNPs.
Non-redundant call set
Variant calls from GATK, MuTect v1, and VarScan 2 were
combined into a single VCF that contains the union of the
variants of all three callers. Ambiguous calls (i.e., different calls at
the same genomic coordinate) were resolved by a simple majority
rule. If there was no majority, the call was rejected. GATK
ReadBackedPhasing was used to retrieve the phasing information
of all variants in the combined VCF (58, 59). The functional
effect of the variants was annotated by SnpEff which predicts
the effects of variants on genes based on reference databases.
To maximize variant annotation we used annotations from the
hg19 (Refseq) and GRCH37.75 (Ensembl) databases (63–65).
This non-redundant, annotated VCF file was used for further
genomics and proteogenomics analyses.
Prediction and Prioritization of Neoantigens
For the identification of neoantigens, only “high confidence”
calls were selected, defined as the set of variants containing all
somatic mutations plus linked SNPs (i.e., those SNPs present on
the same allele as the somatic mutation) detected by MuTect v1
alone or by a combination of at least two of the three variant
callers described above. The novel amino acid generated by each
single nucleotide somatic mutation was placed at the center of
a 31mer peptide that also included any amino acid changes
resulting from non-synonymous linked SNPs. In the case of
a somatic indel mutation, the entire polypeptide encoded by
the new open-reading frame plus the upstream 24 amino acids
could be subjected to HLA ligand prediction. However, for the
described three PDAC samples this option was disabled.
HLA-I and HLA-II ligands were predicted by the
MixMHCpred.v2.0.2 and MixMHC2pred.v1 algorithms,
respectively (66–68). Both algorithms have been trained on
naturally presented peptides and compute the likelihood of a
peptide to bind to one of a given set of HLA alleles. Mutant
peptides of sizes ranging from 9 to 12 and 12 to 19 amino acids,
derived from the 31mer were supplied as input for HLA-I and
HLA-II predictions, respectively, using patient-specific allotypes
as determined by HLA typing (Supplementary Table 1).
Tissue-specific gene expression data was downloaded from
The Genotype-Tissue Expression (GTEx) project, a public
resource that contains data from 53 non-diseased tissues across
nearly 1,000 individuals (69). We used a custom R script to
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retrieve gene expression values, based on GTEx v7 publicly
available data. The 90th percentile expression of the wild type
gene in the tissue-derived tumor was reported from GTEx data,
and mutations in genes not expressed (TPM < 1) in pancreas
were excluded.
Due to the intrinsic content and properties of protein
sequences, HLA ligands are not distributed equally along proteins
and tend to cluster in hotspots. We captured this information
across dozens of cell types in our ipMSDB database (70). The
overlap of the wild-type-form of a mutant peptide with a hotspot
in ipMSDB was calculated, as well as the level of presentation of
the source protein. Any mutant peptide matching any wild-type
sequence in SwissProt (71) or found in the reference GRCh37
(64) proteome was filtered out.
Finally, we used a custom python script to design the best long
peptide(s) for every mutation, encompassing the highest possible
number of HLA-I and HLA-II binding peptides (MixMHCpred
and MixMHC2pred %Rank < 5% or found in ipMSDB). Long
peptides were ranked by the minimum p-value of the predicted
HLA-I neoantigens, and the top 10 long peptides were selected.
Proteogenomics
For every sample, we created a reference fasta file where residue
mutation information was added to the header of the affected
translated transcripts, in a format compatible with MaxQuant
v1.5.9.4i as previously reported (72). We used the GENCODE
v24 (73) (GRCh37 human reference assembly, downloaded from
https://www.gencodegenes.org/human/release_24lift37.html) as
the standard reference dataset (89,543 entries). We parsed the
GENCODE comprehensive gene annotation file, in GFF3 format,
to extract genomic coordinate information for every exon.
These coordinates were compared with sample-specific variant
coordinates to derive non-synonymous amino acid changes
within each protein.
For every patient, we searched the immunopeptidomics MS
data against the patient-specific customized reference database,
including a list of 247 frequently observed contaminants. The
enzyme specificity was set as unspecific, and peptides with
a length between 8 and 25 AA were allowed. The second
peptide identification option in Andromeda was enabled. A false
discovery rate (FDR) of 5% was required for peptides and no
protein FDR was set. The initial allowed mass deviation of the
precursor ion was set to 6 ppm and the maximum fragment
mass deviation was set to 20 ppm. Methionine oxidation and
N-terminal acetylation were set as variable modifications.
PEP-DC Manufacturing
The PEP-DC vaccine is composed of autologous monocyte-
derived DC pulsed with personalized peptides (PEP). Monocytes
are enriched from a fresh leukapheresis using CD14+ cells
selection on the CliniMACS Prodigy (Miltenyi). This process
is GMP compliant and allows for a fast and reliable monocyte
selection in a closed system. Purifiedmonocytes are differentiated
into immature monocyte-derived DC (iDC) by a 5 days culture
in the presence of IL-4 and GM-CSF. On day 6, iDC are then
loaded overnight with 10 long peptides andmatured/activated for
6–8 h using a maturation cocktail composed of MPLA and IFNγ.
Cells are finally harvested and cryopreserved as vaccine doses (5–
10 × 106 cells per dose). For each injection of PEP-DC vaccine,
one dose is thawed, washed and resuspended in NaCl 0.9%
supplemented with 1% human albumin before being transferred
into syringes and stored at 2–8◦C until administration.
Immunogenicity Assessment of PEP-DC
Candidates Pre-immunization
The immunogenicity the long peptides was evaluated in
cryopreserved peripheral blood mononuclear cells (PBMC) from
the three subjects as described (74). PBMC were thawed, rested
overnight in RPMI 10% FBS with Penicillin/Streptomycin. For
the in vitro stimulation (IVS), cells were plated in 24- to 96-
well plates at 2 × 106 cells per well in RPMI, 8% human
serum supplemented with Penicillin/Streptomycin, 50µM beta-
mercaptoethanol and recombinant human IL-2 at a final
concentration of 100 UI/ml. The cells were stimulated with
peptide pools containing 1µg/ml of each candidate peptide. At
day 12, intracellular cytokine stainings (ICS) were performed.
Each individual well was splitted in two identical fractions
and one fraction only was re-challenged with 1µg/ml of the
corresponding peptide for 16–18 h at 37◦C and 5% CO2 in
presence of 1 µg of brefeldin A (Golgiplug, BD). As a positive
control, cells stimulated with staphylococcal enterotoxin B
(SEB) at a concentration of 0.25 ng/ml. After 16–18 h of re-
stimulation with individual long peptides, cells were harvested
and stained with anti-CD3, anti-CD8, anti-CD4, anti-IL-2, anti-
TNF-α, anti-IFN-γ (BD biosciences), and with viability dye
(Life technologies). Flow cytometry was performed using a
four-lasers Fortessa (BD biosciences) and analyzed with FlowJo
v10 (TreeStar).
RESULTS
We here present a novel study were a vaccination schedule
is incorporated in the SOC chemotherapy adjuvant setting
in patients with non-metastatic resectable pancreatic
adenocarcinoma followed by nivolumab (an antibody against
PD-1), to boost and maintain the vaccine’s effect (Figure 1). The
study was optimally designed to offer innovative cancer vaccines
for a PDAC patient population that on one hand would fit the
course of standard of care, and on the other hand will be feasible
in terms of the time required for the process of antigen discovery
and the manufacturing of the vaccine.
It has been correctly pointed out that putting a mutanome-
based individualized treatment concept into practice requires
both highly interdisciplinary research and an innovative drug
development process (75). To fit the tight schedule of the
clinical trial, a period of 5 weeks was dedicated for antigen
discovery. Upon reception of a pair of tumor tissue sample and
matched PBMCs, DNA extraction is performed for whole exome
sequencing and HLA typing, and the tumor tissue sample is
processed for purification of HLA-I and HLA-II peptides for
MS analyses. Within the 2 weeks required for sequencing the
DNA samples, HLA typing and MS analyses are completed.
The following 2 weeks are dedicated for executing the NeoDisc
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FIGURE 1 | Clinical trial study design.
pipeline, for data mining and for manual inspection of the data
and results, leading to the selection of 10 long optimally designed
neoantigens. Finally, the production needs to be “on demand,”
cost-effective, rapid, and compliant with Good Manufacturing
Practice (GMP).
NeoDisc Pipeline for Neoantigen Discovery
in PDAC
We here tested the feasibility of prioritizing neoantigens in
PDAC as targets for our PEP-DC vaccine in three PDAC
patients, 14JQ, 154H, and 16AY. The NeoDisc pipeline integrates
multiple types of data input from next generation sequencing
data, MS immunopeptidomics datasets, and publicly available
resources (Figure 2). First, the NeoDisc pipeline requires a
list of non-synonymous somatic mutations that affect protein-
coding regions as identified by three different mutation-calling
algorithms: MuTect, VarScan2, and GATK. A combined VCF
file is generated and annotated with amino acid changes
and transcript information. To increase accuracy, only “high
confidence” calls were selected, defined as the set of somatic
mutations detected by MuTect alone or by a combination of at
least two of the three variant callers described above. As expected,
the mutational load in the three PDAC patients was low, with 60,
39, and 23, non-synonymous somatic mutations in 14JQ, 154H,
and 16AY, respectively, which is within the range previously
reported (53). Among them, we detected mutations in predicted
driver genes, the MLLT4 (Ser1708Ala) and PTPN12 (Gly532Glu)
(76–78). We then attempted to identify personalized neoantigens
using two different approaches; direct identification with mass
spectrometry and by prediction of HLA ligands encompassing
any of these mutations.
We first performed MS immunopeptidomics analyses on
exactly the same tumor tissue used for the genomics analysis
from the three PDAC patients, and applied a proteogenomics
pipeline as previously described (72) in order to identify
neoantigens naturally presented in the PDAC tissues. We
have identified 11,437, 4,437, and 6,158 HLA-I and 1,569,
448, and 3,319 HLA-II peptides, from the 14JQ, 154H,
and 16AY tumor tissues, respectively (Supplementary Table 2).
However, no neoantigens could be identified by MS. Either
many of the potential neoantigens remain undetected in
the MS-based analyses because of the lack of sensitivity, or
they might not be naturally presented. The likelihood of
detecting neoantigens by discovery MS increases with the overall
depth of ligandomic data available and with the mutational
load. Here, both aspects were not sufficient to successfully
detect neoantigens.
Additional tumor-associated antigen (TAAs) derived HLA
ligands are frequently identified by MS, such as “normal”
(wild-type) proteins overexpressed or restricted to tumors (e.g.,
MelanA, Tyrosinase, PMEL in melanoma; NY-ESO in multiple
cancer types). Such targets have been exploited in innovative
personalized vaccines and T cell based therapies (79, 80).
We have identified multiple TAAs in the immunopeptidome
for each of the three PDAC patients, including the testis-
specific protein bromodomain testis-specific protein (BRDT),
L-lactate dehydrogenase C chain (LDHC), outer dense fiber
protein 2 (ODF2), coiled-coil domain-containing protein 110
(CCDC110), tumor associated antigens mesothelin (MSLN),
mucin-1 (MUC1), prolyl endopeptidase FAP (FAP), and the
cellular tumor antigen p53 (TP53) (Supplementary Table 2).
Nevertheless, after thorough data mining, we estimated that these
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FIGURE 2 | Schematic overview of NeoDisc pipeline for prioritization of neoantigens in PDAC for the design of optimally long peptides for vaccination.
ligands were unlikely to be immunogenic and therefore have
decided not to include them in the vaccine.
Prioritization of Neoantigens and Design of
Long Peptides
Consequently, in the three PDAC patients, the selection of targets
was based exclusively on prediction of neoantigens. To increase
accuracy, the “high confidence” calls were selected, and a list of
31 mer peptides with mutation in the middle position was then
generated and subjected to binding predictions of HLA class I (9–
12 mers) and class II (12–19 mers) with the MixMHCpred.v2.0.2
and MixMHC2pred.v1 algorithms, respectively (66, 68, 81). Both
algorithms have been trained on naturally presented peptides
and compute the likelihood of a peptide to bind to one of
the given set of the patient HLA alleles. We have previously
showed that large scale immunopeptidomics dataset may help
in prioritizing predicted neoantigens (70, 82). Therefore, we
mapped the list of predicted neoantigens on our ipMSDB
ligandomic database that contains a million of HLA-I and HLA-
II ligands. The overlap between the predicted neoantigen and
the wild-type (WT) form present in ipMSDB was determined,
as well as the level of presentation of the source genes. These
values were considered for prioritization; neoantigens matching
exactly WT counterparts in ipMSDB were prioritized (Table 1).
Mutated source genes that were underrepresented in ipMSDB
were excluded. In addition, we excluded predicted neoantigens
that are identical to other WT sequences in the human proteome
(GRCh37 Genome assembly and UniProt database) and all
predicted neoantigens derived from highly mutated genes, which
are likely to be false positives. Finally, we excluded genes that
are known not to be expressed in pancreas (TPM < 1 in GTEx).
For each mutation, we designed a few long peptides covering as
many predicted HLA-I and HLA-II neoantigens as possible. We
ranked the mutations in the format of long peptides according
to the best predicted binding affinity to HLA-I alleles (%Rank
≤ 5% MixMHCpred.v2.0.2), the number of HLA-I and HLA-II
predicted neoantigens harboring the mutation, and the number
of represented HLA alleles. Finally, for each mutation we selected
the shortest long peptide covering as many predicted HLA-I and
HLA-II neoantigens (Figure 3) and completed the list of ten long
peptides (PEP).
DC Vaccine Production
The DC-vaccine used in this study is a frozen suspension of
patient-specific, ex vivo cultured autologous monocyte derived
DCs loaded with synthetic neoantigen (personalized) peptides.
The proprietary name for the biological product comprising
this substance is PEP-DC, which refers to Personalized Peptides
loaded onto autologous DCs. Manufacturing of PEP-DC consists
of five main steps described in Figure 4, starting with peptides
identification and manufacturing. We have tested and validated
this production process with healthy donor leukapheresis and
peptides mixes of up to 9 peptides. Indeed, because of the
peptide length, some synthesis failure should be expected even
after sequence optimization and careful peptide selection. Based
on three experimental batches, we can evaluate that PEP-DC
process leads to the production of 2.8 ± 2.1 × 108 PEP-DC
cells, corresponding to 56 ± 41 PEP-DC cryopreserved vaccine
doses (based on 5.0 × 106 cells per dose) per manufacturing
run. Specifications of the final product ensure safety (sterility,
mycoplasma, endotoxin), viability (Trypan blue exclusion),
identity (phenotype), and functionality (IL12p70 secretion upon
maturation) of the PEP-DC vaccine (Table 2). For each vaccine
injection, a PEP-DC dose is thawed, washed and reconstituted
NaCl-Albumin before injection. Viability is checked on each
reconstituted dose with a target of ≥60.0% viable cells. All
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TABLE 1 | Basic clinical information and detailed information about the 10 optimally designed long peptides for each patient.
Rank Chromosome
position
Gene Expression
in
pancreas,
GTEx
[TPM]
Mutation Gene driver
and
mutation
status
Long peptide sequence ipMSDB HLA-I ipMSDB
HLA-II
Lowest
HLA-I
binding
pval
Lowest
HLA-II
binding
pval
#
predicted
peptides
# HLA-I
alleles
# HLA-II
alleles
14JQ, PDAC, 60 NON-SYNONYMOUS SOMATIC MUTATIONS
1 16_8994451 USP7 11.509 p.Tyr749Asp LYEEVKPNLTERIQDDDVSLDKALDE EXACT 0.002 0.01209 31 4 3
2 7_27169740 HOXA4 1.06 p.Ala205Thr VVYPWMKKIHVSTVNPSYNGGEPKRSRT EXACT EXACT 0.004 0.0005 58 3 7
3 9_33797978 PRSS3 13983 p.Val175Ile TLDNDILLIKLSSPAIINSRVSAISLPT EXACT INCLUDED 0.02 0.00096 39 4 7
4 14_105415346 AHNAK2 1.162 p.Thr2148Ala AHLQGDLTLANKDLTAKDSRFKM EXACT PARTIAL 0.002 0.00914 31 3 2
5 1_17083776 MST1L 34.35 p.Arg674Leu ARSRWPAVFTLVSVFVDWIHKVMRLG 0.0001 0.00578 54 3 6
6 6_168366581 MLLT4 11.744 p.Ser1708Ala Driver LPRDYEPPSPAPAPGAPPPPPQRNAS 0.0001 0.00054 80 3 3
7 8_52732961 PCMTD1 16.471 p.Pro342Thr EPPQNLLREKIMKLTLPESLKAYLT PARTIAL PARTIAL 0.0008 0.00098 66 4 3
8 6_150001239 LATS1 3.182 p.Asp789Asn KDNLYFVMDYIPGGNMMSLLIRMGIFPE PARTIAL 0.0009 0.00126 58 3 7
9 3_123419461 MYLK 3.273 p.Asp952Asn Passenger RKVHSPQQVNFRSVLAKKGTSKT 0.001 0.01599 24 4 3
10 1_155697428 DAP3 12.728 p.Leu168Phe IPDAHLWVKNCRDFLQSSYNKQRFD 0.002 0.00521 45 4 2
154H, PDAC, 39 NON-SYNONYMOUS SOMATIC MUTATIONS
1 2_85576579 RETSAT 17.724 p.Arg309Trp IAFHTIPVIQWAGGAVLTKATVQSVL EXACT EXACT 0.0004 0.00026 65 5 4
2 12_51453191 LETMD1 14.494 p.Asn367Asp AELSLLLHNVVLLSTDYLGTRR EXACT EXACT 0.006 0.00298 50 4 4
3 20_34457413 PHF20 2.4 p.Arg288Gly NSQTLQPITLELRRGKISKGCEVPL EXACT 0.02 0.03246 19 4 2
4 3_57908703 SLMAP 3.553 p.Lys783Gln KQSITDELQQCKNNLKLLREK 0.0007 0.00357 40 3 2
5 2_241700220 KIF1A 11.548 p.Ser769Phe KKVQFQFVLLTDTLYFPLPPDLLPPEAA 0.0008 0.00201 72 5 5
6 2_238253286 COL6A3 16.075 p.Arg2459Trp VAVVTYNNEVTTEIWFADSKRKSVLLDK 0.0009 0.00133 61 5 5
7 13_96592287 UGGT2 3.986 p.Val579Gly KKDQNILTVDNVKSGLQNTF 0.002 0.01697 24 6 3
8 7_77256591 PTPN12 12.375 p.Gly532Glu Driver DRLPLDEKEHVTWSFHGPENAIPI PARTIAL PARTIAL 0.003 0.0391 12 6 1
9 18_55352319 ATP8B1 10.673 p.Asn486Lys DHRDASQHKHNKIEQVDFSWNTYA 0.003 0.0339 14 5 2
10 8_9627645 TNKS 3.91 p.Gly1257Glu HRQMLFCRVTLEKSFLQFSTMKMAHA PARTIAL PARTIAL 0.003 0.00039 39 6 5
16AY, PDAC, 23 NON-SYNONYMOUS SOMATIC MUTATIONS
1 17_15134320 PMP22 11.978 p.Gly133Ser HPEWHLNSDYSYSFAYILAWVAFPLALL EXACT 0.0004 0.00018 86 4 8
2 X_54014354 PHF8 5.113 p.Ser621Tyr LLMSNGSTKRVKSLYKSRRTKIAKKVDK 0.0001 0.0075 48 5 2
3 9_33794809 PRSS3 13983 p.Ser5Asn MRETNVFTLKKGRSAPLVF 0.0004 0.00558 10 4 3
4 12_9085452 PHC1 9.639 p.Gln467Lys TQQVPPSQSQQKAQTLVVQPMLQSSPL PARTIAL 0.0004 0.0044 42 5 6
5 19_1037681 CNN2 20.083 p.Asp259Asn APGTRRHIYDTKLGTNKCDNSSMSLQMG 0.0008 0.01696 27 5 5
6 20_50704942 ZFP64 1.539 p.Arg187Leu YASRNSSQLTVHLLSHTGDTPFQ 0.002 0.00077 40 3 4
7 12_31254897 DDX11 5.459 p.Arg728His LRQVHAHWEKGGLLGHLAARKKIFQE 0.003 0.00764 37 3 2
8 11_32954416 QSER1 3.78 p.Asn409Asp SSNQQEVLSSVTNEDYPAQTRDLSSVSQ PARTIAL 0.003 0.00478 39 3 4
9 1_27177681 ZDHHC18 4.114 p.His299Tyr FFSIWSILGLSGFYTYLVASNLTTNEDI PARTIAL 0.005 0.00012 106 4 8
10 20_60892518 LAMA5 23.906 p.Arg2465Gln AKEELERLAASLDGAQTPLLQRMQT PARTIAL PARTIAL 0.008 0.00763 41 5 6
The position of the mutation in the long peptide is indicated in red. ipMSDB HLA-I and ipMSDB HLA-II columns show the matching of the WT counterpart of the predicted neoantigen in the ipMSDB. Prediction of driver genes and
mutation status annotations are derived from IntOGen database.
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FIGURE 3 | Example for the design of the minimally long peptide covering the mutation Arg288Gly in PFH20 gene identified in 154H PDAC patient.
FIGURE 4 | Schematic overview of PEP-DC manufacturing process and timelines.
PEP-DC batches prepared in this pilot study met specification
for product release as described in Table 2. This confirms that
our GMP-compliant manufacturing process is suitable for the
production PEP-DC.
Pre-immunization Immunogenicity of PEP
Candidates
Even though immune responses against neoantigens prior to
vaccination are typically rare, we decided to test if any of the 10
PEP long peptides may be recognized by autologous T cells from
peripheral blood. Pre-immunization immunogenicity was tested
for the three PDAC patients. Although some of the long peptides
failed the synthesis quality control and could not be tested, CD4+
T-cell responses against PEP candidates were detected against at
least one long peptide in all three donors, while no CD8+ T cell
responses could be detected (Figure 5).
DISCUSSION AND INNOVATION
Over the last 10 years immunotherapy has changed the
treatment landscape of several tumor types in metastatic setting.
Management of patients with non-metastatic cancer relies
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on multimodality treatment that includes surgical resection
depending on tumor type and peri-operative chemotherapy. In
PDAC, despite these aggressive measures, the high propensity
of relapse has a detrimental effect on survival. The high
metastatic potential is due to the presence of micrometastasis
at systemic sites in patients with early-stage pancreatic cancer
(83). In this proof of concept trial, our aim is to demonstrate
that in such very aggressive diseases, there is a need to act
without any delay, and early immunomodulation may be the
key response.
TABLE 2 | Specification for release for the final product of PEP-DC doses.
Test Analytical procedure Specification
PEP-DC at day 6
(final product)
Sterility BacTEC (aerobic and
anaerobic)
No growth
Mycoplasma MycoSeq Negative
Endotoxin Endosafe ≤10.0 EU/mL
Cell count Manual cell count by
Trypan blue exclusion
≥45.0 × 106 viable
cells
Viability ≥60.0% viability
Cell
purity/identity
Flow cytometry ≥60.0% live
HLA-DR+CD86+
cells
≤20.0%
CD14+ cells
Culture supernatant
at day 6 after
maturation
Functionality
IL-12p70
ELISA ≥50.0 pg/mL
Although pancreatic cancer patients present high frequencies
of functional tumor-reactive T cells in the bone-marrow and
blood (84), and show an averagemutation burden similar to other
solid tumors (85), parsing tumor immune microenvironment
(TME) of pancreatic cancer seems to be a challenge. In PDAC,
tumor-specific CTLs become “trapped” in the peritumoral tissue
and in the tumor stroma, not reaching pancreatic tumor cells in
sufficient amounts (86, 87). Additionally, exhaustion of effector
CD8+ T-cells by the TME as well as hampered recruitment of
cDC1s by downregulating CCL4 signaling upon constitutively
active β-catenin signaling may explain the ineffective antitumoral
response, which underscores the importance of endogenous DCs
for initiating anti-tumor immunity.
Rationale for Combination Immunotherapy
in PDAC
Currently, clinical benefit using different agents in monotherapy
is very limited in PDAC. Therefore, combination strategies are
required, in order to obtain a synergistic effect on potential
efficacy, yet keeping expected adverse events under manageable
conditions. Therefore, it is important to establish both the
scientific rationale of the proposed combination, as well as the
best timing for introducing each component.
Treatment of metastatic cancer essentially relies on cytotoxic
drugs that kill tumor cells or hinder their proliferation.
Although a primary goal of anti-cancer chemotherapy is the
tumor mass reduction, it is now clear that off-target effects,
especially directed to the host immune system, may reduce the
FIGURE 5 | T-cell responses in donors 14JQ, 16AY, and 154H against long peptides. The percentage of IFN-γ-producing T cells are shown. Black (unstim) and white
(SEB) bars represents negative and positive controls, respectively. Positive peptides are identified in red.
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immunosuppressive activity of malignant cells and cooperate
for successful tumor eradication (88). Gemcitabine (GEM) is
a chemotherapeutic agent acting as a nucleoside analog that
also targets ribonucleotide reductase by inactivating the enzyme
irreversibly. It is used in various carcinomas such as non-small
cell lung cancer, pancreatic cancer, bladder cancer, and breast
cancer, and it represents the primary systemic agent for the
treatment of pancreatic cancer. On standard dose schedules
in patients with pancreatic cancer, the drug is associated with
manageable toxicity, and its administration has led to a survival
benefit both in the primary and adjuvant settings (89, 90).
In advanced pancreatic cancer patients, GEM therapy may
decrease memory T-cells, promote naive T-cell activation (91),
and induce the proliferation of CD14+ monocytes and CD11c+
DC (92). GEM is also able to induce apoptotic destruction of
tumor cells and potentially load the immune system with large
amounts of tumor antigen, but this is not enough to initiate a
protective antitumor response and adjuvant immunotherapy is
required (93).
A peptide cocktail vaccine OCV-C01 containing epitope
peptides [coding for vascular epithelial growth factor receptor
(VEGFR1 ad VEGFR2)] was investigated in combination with
GEM in the adjuvant treatment for resected pancreatic cancer
patients (n = 30) in a single arm multicenter Phase II study.
OCV-C01 combined with GEM was tolerable with a median DFS
of 15.8months (and aDFS rate at 18months of 34.6%), which was
favorable compared with previous data for resected pancreatic
cancer (94). In another phase I pilot study, a Wilms tumor gene-
1 peptide-pulsed DC vaccination was evaluated in combination
with GEM as a first-line of treatment in 10 patients with advanced
pancreatic cancer. WT1 peptide-pulsed DCGEM is feasible, well-
tolerated, and effective for inducing anti-tumor T-cell responses
(95). Kimura et al. evaluated a DC-based vaccine alone or in
combination with lymphokine-activated killer (LAK) cells, along
with gemcitabine and/or S-1 in 49 patients with inoperable
pancreatic cancer (96). Of these patients, two manifested a
complete remission, five a partial remission, and 10 had stable
disease. The median survival of these individuals was 360 days,
which appeared to be longer than what could be achieved
with gemcitabine and/or S-1. Thus, the combination of DC-
based immunotherapy and chemotherapy seems well-tolerated
by advanced PDAC patients but warrants further investigation
through combination with ICB or other immunotherapies. In
our study, we build on the gemcitabine/capecitabine backbone
for not fit pancreatic cancer population (ECOG PS 1 or 2) and
explore the additive benefits of DC-vaccination from the 5th cycle
of chemotherapy, followed by nivolumab treatment.
In pancreatic cancer, a possible explanation for the therapeutic
failure of PD-1/PD-L1 blockade therapy is the lack of
natural infiltration of effector immune cells in most cases
(17, 18, 20). Vaccine-based immunotherapy is a potential
strategy to activate effector T cell trafficking into the TME.
Additionally, it has been shown that the repertoire of clonally
expanded tumor antigen-reactive cells within TILs expresses
PD-1 (97), either in spontaneous responses or vaccine-
mediated. Furthermore, vaccination induces intratumoral PD-L1
expression (98), suggesting a role for PD-1 blockade in enhancing
vaccine efficacy (98, 99). Consistently, in a preclinical model
for pancreatic cancer, GVAX administration (a cancer vaccine
composed of allogeneic pancreatic tumor cell line engineered
to secrete GM-CSF) induced upregulation of PD-L1 expression
when compared to untreated human and mouse pancreatic
tumors. Combination therapy with GVAX and PD-1/PD-L1
blockade improved survival, and correlated with increased
CD8+ T infiltration into pancreatic tumors (100).
Currently very few clinical trials combining cancer vaccines
and PD-1/PD-L1 blockade have been reported in the setting
of pancreatic cancer. Combination strategies using DC vaccines
with ICB should generate an additive effect (98, 99, 101), with low
additional toxicity due to DC vaccination (102, 103). Nesselhut
et al. demonstrated that the efficacy of DC based therapy can be
improved by blockade of PD-L1, enhancing the T-cell specific
response (104). Dose and schedule for anti-PD-1 therapy and
vaccines have been minimally studied; however, both PD-1 on
activated T cells and PD-L1 on tumors appear rapidly following
exposure to interferon (105), suggesting that early application
of PD-1 blockade may be important. For this reason, we have
decided to start nivolumab treatment 3 weeks after the end of
SOC treatment, aiming also to avoid potential toxicities due to
combined chemo-ICB.
Because Treg may persist despite checkpoint blockade,
Treg depletion in conjunction with checkpoint blockade and
vaccination may enhance clinical anti-tumor efficacy. Systematic
reviews of the results of aspirin in cardiovascular studies have
suggested that low-dose aspirin reduces overall cancer incidence
and mortality including in pancreatic cancer (106, 107). In terms
of its mechanism (108), it has been shown that non-steroidal anti-
inflammatory drugs may limit carcinogenesis and enhance the
immune response by (a) preventing prostaglandin E2 (PGE2)-
mediated inhibition of DCs and reducing the transition of
monocytes to immunosuppressive MDSCs (109); (b) reducing
the inhibitory potential of Tregs induced by PGE2 (110); and
(c) abrogating the PGE2 induced suppression of effector T-cell
proliferation by regulatory T cells (111), therefore contributing
to enhanced immune surveillance. Furthermore, PGE2 inhibitors
like aspirin can counteract the FasL mediated elimination of
activated lymphocytes by the tumor endothelial cells, as well
as reduce the immunosuppressive conditions, thus enhancing
the immune response against the tumor. We therefore consider
that blockade of PGE2 in cancers using aspirin can reverse the
endothelial barrier and synergize with vaccination allowing T
cell infiltration. Consequently, we will use aspirin all along our
study, which we expect to synergize with T cell activation by
PD-1/PD-L1 blockade.
Neoantigen Prediction and Selection for
PEP-DC
Identification and selection of targets for neoantigen based
vaccines is challenging. Mass spectrometry has been instrumental
for the identification of cancer-associated antigens among the
endogenously presented peptides. In recent years, dedicated
computational pipelines for proteogenomic applications
facilitated the direct identification of neoantigens by MS in
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murine and human cancer cell line models (49, 112–115), B
cell lymphomas (116), and melanoma tissues (72) as well as
other cryptic peptides resulting from unconventional coding
sequences in the genome (117, 118). However, only a handful
of neoantigens have been identified by MS in a given sample,
and typically in high mutational load tumors such as melanoma
(72). Indeed, we could not identify with discovery MS-based
immunopeptidomics neoantigens in the three investigated
PDAC samples. While several tumor-associated antigens were
identified, after literature mining we concluded that these
antigens might be poorly immunogenic, and in these three cases
we decided to exclude non-mutated targets.
The prioritization and selection of neoantigens for
personalized vaccines in low mutational load tumors like
PDAC is largely performed with HLA ligand interaction
prediction algorithms. The performance of such tools has
improved significantly with the incorporation of MS HLA
ligand elution data in the training of the algorithms, both
for HLA-I (81, 119–121), and more recently for HLA-II (68).
Furthermore, interrogation of properties of the thousands of
different source-proteins has revealed biological determinants
that correlate with presentation, such as level of translation and
expression, turnover rate, proteasomal cleavage specificities,
hotspots, and biological functions. Integrating such variables into
a single predictor further improves prediction of neoantigens
(70, 72, 120, 122). Because predictors of immunogenicity are still
immature (123) false positives are inevitably included among
the predicted neoantigens, which may eventually be included in
a vaccine.
A main innovative aspect of our study is the identification of
PDACmutated neoantigens. We have designed NeoDisc, a novel
proteogenomics antigen discovery pipeline for identification
and selection of neoantigens, and we apply it for the first
time in PDAC. NeoDisc integrates multiple state of the
art prediction tools, large-scale ligandomic database, and a
unique personalized and optimized design of long peptides
that maximizes the likelihood that the selected mutations will
eventually be presented by the HLA-I and HLA-II complexes
on the loaded DCs. While in this PEP-DC study the existence
of pre-existing immune responses against the long peptides is
not a prerequisite for inclusion in the vaccine, such analysis
is performed as part of a large translational program that
aims to provide extensive immunogenicity training data that
will allow future development to improve the performance
of NeoDisc.
This proof of concept study aimed to assess specifically
the feasibility of prioritizing immunogenic neoantigens with
NeoDisc. Indeed, we were able to confirm for the three
patients pre-existing immune responses against in total four long
neoantigen peptides with autologous peripheral CD4+ T cells.
No CD8+ T cell responses could be detected. This might be
related to the low frequency of neoantigen specific CD8+ T
cells. Alternative strategies could have been more sensitive to
detect CD8+ T-cell responses, such as peptide-MHC multimers
screening. However, unfortunately, there were no PBMC left to
test this hypothesis. The clinical trial has not started yet, and
therefore the investigation of immune responses post-vaccine
could not be performed. This trial will give us the opportunity to
(1) better understand PDACTME since wewill be able to evaluate
the mutational rate in PDAC and predict the presentation of
neoantigens; (2) assess the frequency of specific T cells to such
mutant epitopes in PDAC patients, before and after treatment
with ICB; (3) validate the immunogenicity of neoantigens and
their therapeutic effect.
In conclusion, PDAC in early-stage remains a deadly disease
with limited treatment options and the development of novel
strategies tailored to individual patients is the key. Our approach
is focused particularly on patients with a borderline performance
status or a comorbidity profile that precludesmultiagent adjuvant
therapy (type folforinox). In this context, we give the opportunity
even in patients with the worst prognosis to have access to
innovative therapies.
DATA AVAILABILITY
The raw data supporting the conclusions of this manuscript
will be made available by the authors. To respect patient
confidentiality, access to the data will be obtained by formal
application to a Data Access Committee that requires researchers
to sign a Data Access Agreement (DAA).
AUTHOR CONTRIBUTIONS
MB-S is responsible for the development of NeoDisc and for
clinical antigen discovery, and wrote the manuscript. BS and FH
developed NeoDisc. JM and HP performed Bristol-Myers Squibb
(BMS) immunopeptidomics experiments. JR and DG developed
MixMHC2perd. CS, DW, andNDprovided the pancreatic cancer
specimens and reviewed the manuscript. AD, KB, and SM
contributed to the clinical trial design and manuscript writing.
GC contributed to the clinical trial design. A-CT and AH
developed the immunogenicity validation data. CB developed
the vaccine clinical grade data. LK developed the clinical grade
vaccine, conceived the clinical study, and wrote the manuscript.
FUNDING
This work was partially supported by the Ludwig Institute for
Cancer Research (MB-S, HP, JM, FH, DG, JR, AH, and LK),
the ISREC Foundation thanks to a donation from the Biltema
Foundation (MB-S, HP, JM, FH, and AH), and institutional
support from Center Hospitalier Universitaire Vaudois. The
clinical study will be financially supported by Bristol-Myers
Squibb (BMS).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.01832/full#supplementary-material
Table S1 | General clinical information and high resolution HLA typing.
Table S2 | List of HLA-I and HLA-II peptides identified by MS-based
immunopeptidomics in the three PDAC tumor samples, including MS intensity,
peptide length and mass, identification score and posterior error probability (PEP),
source proteins and gene names.
Frontiers in Immunology | www.frontiersin.org 13 August 2019 | Volume 10 | Article 1832
Bassani-Sternberg et al. Personalized Vaccine for Pancreatic Cancer
REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424.
doi: 10.3322/caac.21492
2. Huang L, Jansen L, Balavarca Y, Babaei M, van der Geest L, Lemmens
V, et al. Stratified survival of resected and overall pancreatic cancer
patients in Europe and the USA in the early twenty-first century: a
large, international population-based study. BMC Med. (2018) 16:125.
doi: 10.1186/s12916-018-1120-9
3. Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic
adenocarcinoma. World J Gastroenterol. (2015) 21:9297–316.
doi: 10.3748/wjg.v21.i31.9297
4. Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S,
Lordick F, et al. What treatment in 2017 for inoperable pancreatic
cancers? Ann Oncol. (2017) 28:1473–83. doi: 10.1093/annonc/
mdx174
5. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Chia-chi Wei
A, Raoul JL, et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial:
A multicenter international randomized phase III trial of adjuvant
mFOLFIRINOX versus gemcitabine (gem) in patients with resected
pancreatic ductal adenocarcinomas. J Clin Oncol. (2018) 36:LBA4001.
doi: 10.1200/JCO.2018.36.18_suppl.LBA4001
6. Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado
M, et al. From first line to sequential treatment in the management of
metastatic pancreatic cancer. J Cancer. (2018) 9:1978–88. doi: 10.7150/jca.
23716
7. Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune
system in cancer progression and vaccine-based immunotherapy. Hum
Vaccin Immunother. (2014) 10:3354–68. doi: 10.4161/hv.34392
8. Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi
N, et al. Overexpression of the Wilms’ tumor gene WT1 in
pancreatic ductal adenocarcinoma. Cancer Sci. (2004) 95:583–7.
doi: 10.1111/j.1349-7006.2004.tb02490.x
9. Ueda M, Miura Y, Kunihiro O, Ishikawa T, Ichikawa Y, Endo I, et al.
MUC1 overexpression is the most reliable marker of invasive carcinoma
in intraductal papillary-mucinous tumor (IPMT). Hepatogastroenterology.
(2005) 52:398–403.
10. Seki K, Suda T, Aoyagi Y, Sugawara S, Natsui M, Motoyama H,
et al. Diagnosis of pancreatic adenocarcinoma by detection of human
telomerase reverse transcriptase messenger RNA in pancreatic juice with
sample qualification. Clin Cancer Res. (2001) 7:1976–81.
11. Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma:
a clinicopathologic study of 304 patients and immunohistochemical
observation for CEA and CA19-9. J Surg Oncol. (1991) 47:148–54.
doi: 10.1002/jso.2930470303
12. Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M,
et al. HER2 overexpression correlates with survival after curative
resection of pancreatic cancer. Cancer Sci. (2009) 100:1243–7.
doi: 10.1111/j.1349-7006.2009.01176.x
13. Maacke H, Kessler A, Schmiegel W, Roeder C, Vogel I, Deppert W, et al.
Overexpression of p53 protein during pancreatitis. Br J Cancer. (1997)
75:1501–4. doi: 10.1038/bjc.1997.256
14. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, et al.
An integrated humoral and cellular response is elicited in pancreatic cancer
by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated
antigen. Int J Cancer. (2009) 125:639–48. doi: 10.1002/ijc.24355
15. Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma:
a review of immunologic aspects. J Invest Med. (2012) 60:643–63.
doi: 10.2310/JIM.0b013e31824a4d79
16. Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Pancreatic
ductal adenocarcinoma: a strong imbalance of good and bad immunological
cops in the tumor microenvironment. Front Immunol. (2018) 9:1044.
doi: 10.3389/fimmu.2018.01044
17. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, et al.
Systemic and local immunosuppression in pancreatic cancer patients. Clin
Cancer Res. (2001) 7(3 Suppl.):925s−32s.
18. Schmidt J, Mocevicius P, Werner J, Ryschich E. The role of the tumor
endothelium in leukocyte recruitment in pancreatic cancer. Surgery. (2012)
152(3 Suppl 1.):S89–94. doi: 10.1016/j.surg.2012.05.027
19. Guerra C, Collado M, Navas C, Schuhmacher AJ, Hernández-Porras I,
Cañamero M, et al. Pancreatitis-induced inflammation contributes to
pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell.
(2011) 19:728–39. doi: 10.1016/j.ccr.2011.05.011
20. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al.
Immune cell infiltration as an indicator of the immune microenvironment
of pancreatic cancer. Br J Cancer. (2013) 108:914–23. doi: 10.1038/bjc.
2013.32
21. Wartenberg M, Zlobec I, Perren A, Koelzer VH, Gloor B, Lugli A,
et al. Accumulation of FOXP3+T-cells in the tumor microenvironment
is associated with an epithelial-mesenchymal-transition-type tumor
budding phenotype and is an independent prognostic factor in surgically
resected pancreatic ductal adenocarcinoma. Oncotarget. (2015) 6:4190–201.
doi: 10.18632/oncotarget.2775
22. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating
anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic
cancer. Int J Cancer. (2003) 103:97–100. doi: 10.1002/ijc.10801
23. Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG,
et al. A novel survival-based tissue microarray of pancreatic cancer
validates MUC1 and mesothelin as biomarkers. PLoS ONE. (2012) 7:e40157.
doi: 10.1371/journal.pone.0040157
24. Tewari N, Zaitoun AM, Arora A, Madhusudan S, Ilyas M, Lobo DN. The
presence of tumour-associated lymphocytes confers a good prognosis in
pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue
microarrays. BMC Cancer. (2013) 13:436. doi: 10.1186/1471-2407-13-436
25. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands
in tolerance and immunity. Annu Rev Immunol. (2008) 26:677–704.
doi: 10.1146/annurev.immunol.26.021607.090331
26. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1)
pathway to activate anti-tumor immunity. Curr Opin Immunol. (2012)
24:207–12. doi: 10.1016/j.coi.2011.12.009
27. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of
lupus-like autoimmune diseases by disruption of the PD-1 gene encoding
an ITIM motif-carrying immunoreceptor. Immunity. (1999) 11:141–51.
doi: 10.1016/S1074-7613(00)80089-8
28. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ,
Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and
function of induced regulatory T cells. J Exp Med. (2009) 206:3015–29.
doi: 10.1084/jem.20090847
29. Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J, et al.
Management of toxicities from immunotherapy: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017)
28(Suppl_4):iv119–42. doi: 10.1093/annonc/mdx225
30. Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer:
barriers and breakthroughs. Ann Gastroenterol Surg. (2018) 2:274–81.
doi: 10.1002/ags3.12176
31. Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E,
et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma:
challenges and recommendations. Clin Cancer Res. (2018) 24:1326–36.
doi: 10.1158/1078-0432.CCR-17-3099
32. Thind K, Padrnos LJ, Ramanathan RK, Borad MJ. Immunotherapy in
pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol.
(2017) 10:168–94. doi: 10.1177/1756283X16667909
33. Wainberg, ZAHH, George B. Phase I study of nivolumab (nivo) + nab-
paclitaxel (nab-P)± gemcitabine (Gem) in solid tumors: interim results from
the pancreatic cancer (PC) cohorts. J Clin Oncol. (2017) 35(Suppl. 4S):412.
doi: 10.1200/JCO.2017.35.4_suppl.412
34. Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic cell-
based immunotherapy: state of the art and beyond. Clin Cancer Res. (2016)
22:1897–906. doi: 10.1158/1078-0432.CCR-15-1399
35. vanWilligenWW, Bloemendal M, GerritsenWR, Schreibelt G, de Vries IJM,
Bol KF. Dendritic cell cancer therapy: vaccinating the right patient at the
right time. Front Immunol. (2018) 9:2265. doi: 10.3389/fimmu.2018.02265
36. Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A,
et al. The feasibility and safety of immunotherapy with dendritic cells
Frontiers in Immunology | www.frontiersin.org 14 August 2019 | Volume 10 | Article 1832
Bassani-Sternberg et al. Personalized Vaccine for Pancreatic Cancer
loaded with CEA mRNA following neoadjuvant chemoradiotherapy and
resection of pancreatic cancer. Int J Gastrointest Cancer. (2002) 32:1–6.
doi: 10.1385/IJGC:32:1:1
37. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected
dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol
Immunother. (2002) 51:669–73. doi: 10.1007/s00262-002-0317-z
38. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, et al. A phase
I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as
adjuvant therapy in patients with resected pancreatic and biliary tumors.
Cancer Ther. (2008) 6:955–64.
39. Rong Y, Qin X, Jin D, Lou W, Wu L, Wang D, et al. A phase I
pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment
of advanced pancreatic cancer. Clin Exp Med. (2012) 12:173–80.
doi: 10.1007/s10238-011-0159-0
40. Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Personalized
approaches to active immunotherapy in cancer. Biochim Biophys Acta. (2016)
1865:72–82. doi: 10.1016/j.bbcan.2015.07.004
41. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin
AV, et al. Signatures of mutational processes in human cancer.Nature. (2013)
500:415–21. doi: 10.1038/nature12477
42. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko
A, et al. Mutational heterogeneity in cancer and the search for new cancer-
associated genes. Nature. (2013) 499:214–8. doi: 10.1038/nature12213
43. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr,
Kinzler KW. Cancer genome landscapes. Science. (2013) 339:1546–58.
doi: 10.1126/science.1235122
44. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk
B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity
in an ipilimumab-responsive melanoma. J Clin Oncol. (2013) 31:e439–42.
doi: 10.1200/JCO.2012.47.7521
45. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al.
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl
J Med. (2014) 371:2189–99. doi: 10.1056/NEJMoa1406498
46. Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, et al. Mutational
profiling of colorectal cancers with microsatellite instability. Oncotarget.
(2015) 6:42334–44. doi: 10.18632/oncotarget.5997
47. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ,
et al. Cancer immunobiology. mutational landscape determines sensitivity
to PD-1 blockade in non-small cell lung cancer. Science. (2015) 348:124–8.
doi: 10.1126/science.aaa1348
48. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L,
et al. Genomic correlates of response to CTLA-4 blockade in metastatic
melanoma. Science. (2015) 350:207–11. doi: 10.1126/science.aad0095
49. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal
J, Petti AA, et al. A dendritic cell vaccine increases the breadth and
diversity of melanoma neoantigen-specific T cells. Science. (2015) 348:803–8.
doi: 10.1126/science.aaa3828
50. Ott PA,HuZ, KeskinDB, Shukla SA, Sun J, BozymDJ, et al. An immunogenic
personal neoantigen vaccine for patients with melanoma. Nature. (2017)
547:217–21. doi: 10.1038/nature22991
51. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M,
et al. Personalized RNA mutanome vaccines mobilize poly-specific
therapeutic immunity against cancer. Nature. (2017) 547:222–6.
doi: 10.1038/nature23003
52. Waddell N, PajicM, Patch AM, Chang DK, Kassahn KS, Bailey P, et al.Whole
genomes redefine the mutational landscape of pancreatic cancer. Nature.
(2015) 518:495–501. doi: 10.1038/nature14169
53. Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, et al.
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal
adenocarcinoma. Sci Rep. (2016) 6:35848. doi: 10.1038/srep35848
54. Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R,
et al. Identification of unique neoantigen qualities in long-term survivors of
pancreatic cancer. Nature. (2017) 551:512–6. doi: 10.1038/nature24462
55. Chong C, Marino F, Pak H, Racle J, Daniel RT, Muller M, et al.
High-throughput and sensitive immunopeptidomics platform reveals
profound interferongamma-mediated remodeling of the human leukocyte
antigen (HLA) ligandome. Mol Cell Proteomics. (2018) 17:533–48.
doi: 10.1074/mcp.TIR117.000383
56. Marino F, Chong C, Michaux J, Bassani-Sternberg M. High-throughput, fast,
and sensitive immunopeptidomics sample processing for mass spectrometry.
Methods Mol Biol. (2019) 1913:67–79. doi: 10.1007/978-1-4939-8979-9_5
57. Li H, Durbin R. Fast and accurate short read alignment with
burrows-wheeler transform. Bioinformatics. (2009) 25:1754–60.
doi: 10.1093/bioinformatics/btp324
58. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A,
et al. The genome analysis toolkit: a mapreduce framework for analyzing
next-generation DNA sequencing data. Genome Res. (2010) 20:1297–303.
doi: 10.1101/gr.107524.110
59. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al.
A framework for variation discovery and genotyping using next-generation
DNA sequencing data. Nat Genet. (2011) 43:491. doi: 10.1038/ng.806
60. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin
L, et al. VarScan 2: somatic mutation and copy number alteration
discovery in cancer by exome sequencing. Genome Res. (2012) 22:568–76.
doi: 10.1101/gr.129684.111
61. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al.
The sequence alignment/map format and SAMtools. Bioinformatics. (2009)
25:2078–9. doi: 10.1093/bioinformatics/btp352
62. Li H. A statistical framework for SNP calling, mutation discovery, association
mapping and population genetical parameter estimation from sequencing
data. Bioinformatics. (2011) 27:2987–93. doi: 10.1093/bioinformatics/
btr509
63. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq):
a curated non-redundant sequence database of genomes, transcripts and
proteins. Nucleic Acids Res. (2007) 35:D61–65. doi: 10.1093/nar/gkl842
64. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, Cline MS, et al.
The UCSC genome browser database: update 2011.Nucleic Acids Res. (2011)
39:D876–82. doi: 10.1093/nar/gkq963
65. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A,
et al. The ensembl variant effect predictor. Genome Biol. (2016) 17:122.
doi: 10.1186/s13059-016-0974-4
66. Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H,
Gannon PO, et al. Deciphering HLA-I motifs across HLA peptidomes
improves neo-antigen predictions and identifies allostery regulating HLA
specificity. PLoS Comput Biol. (2017) 13:e1005725. doi: 10.1371/journal.pcbi.
1005725
67. Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, et al. The
length distribution and multiple specificity of naturally presented HLA-I
ligands. J Immunol. (2018) 201:3705–16. doi: 10.4049/jimmunol.1800914
68. Racle J, Michaux J, Rockinger GA, Arnaud M, Bobisse S, Chong C, et al.
Deep motif deconvolution of HLA-II peptidomes for robust class II epitope
predictions. bioRxiv. (2019) 539338. doi: 10.1101/539338
69. Consortium GT. The genotype-tissue expression (GTEx) project. Nat Genet.
(2013) 45:580–5. doi: 10.1038/ng.2653
70. Muller M, Gfeller D, Coukos G, Bassani-Sternberg M. ‘Hotspots’ of
antigen presentation revealed by human leukocyte antigen ligandomics
for neoantigen prioritization. Front Immunol. (2017) 8:1367.
doi: 10.3389/fimmu.2017.01367
71. Bairoch A, Apweiler R. The SWISS-PROT protein sequence database
and its supplement TrEMBL in 2000. Nucleic Acids Res. (2000) 28:45–8.
doi: 10.1093/nar/28.1.45
72. Bassani-Sternberg M, Braunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm
S, et al. Direct identification of clinically relevant neoepitopes presented on
native human melanoma tissue by mass spectrometry. Nat Commun. (2016)
7:13404. doi: 10.1038/ncomms13404
73. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M,
Kokocinski F, et al. GENCODE: the reference human genome
annotation for The ENCODE project. Genome Res. (2012) 22:1760–74.
doi: 10.1101/gr.135350.111
74. Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, et al.
Sensitive and frequent identification of high avidity neo-epitope specific CD8
(+) T cells in immunotherapy-naive ovarian cancer. Nat Commun. (2018)
9:1092. doi: 10.1038/s41467-018-03301-0
75. Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U. Targeting the
heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer
Res. (2016) 22:1885–96. doi: 10.1158/1078-0432.CCR-15-1509
Frontiers in Immunology | www.frontiersin.org 15 August 2019 | Volume 10 | Article 1832
Bassani-Sternberg et al. Personalized Vaccine for Pancreatic Cancer
76. Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder
MP, Jene-Sanz A, et al. IntOGen-mutations identifies cancer drivers across
tumor types. Nat Methods. (2013) 10:1081. doi: 10.1038/nmeth.2642
77. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X,
et al. Landscape of somatic mutations in 560 breast cancer whole-genome
sequences. Nature. (2016) 534:47–54. doi: 10.1038/nature17676
78. Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R,
et al. Combinatorial inhibition of PTPN12-regulated receptors leads to a
broadly effective therapeutic strategy in triple-negative breast cancer. Nat
Med. (2018) 24:505–11. doi: 10.1038/nm.4507
79. Reinhardt C, Zdrojowy R, Szczylik C, Ciuleanu T, Brugger W, Oberneder
R, et al. Results of a randomized phase II study investigating multipeptide
vaccination with IMA901 in advanced renal cell carcinoma (RCC). J Clin
Oncol. (2010) 28:4529. doi: 10.1200/jco.2010.28.15_suppl.4529
80. Wick W, Dietrich P-Y, Kuttruff S, Hilf N, Frenzel K, Admon A,
et al. GAPVAC-101: first-in-human trial of a highly personalized peptide
vaccination approach for patients with newly diagnosed glioblastoma. J Clin
Oncol. (2018) 36:2000. doi: 10.1200/JCO.2018.36.15_suppl.2000
81. Bassani-Sternberg M, Gfeller D. Unsupervised HLA peptidome
deconvolution improves ligand prediction accuracy and predicts cooperative
effects in peptide-HLA interactions. J Immunol. (2016) 197:2492–9.
doi: 10.4049/jimmunol.1600808
82. Gfeller D, Bassani-Sternberg M. Predicting antigen presentation-what
could we learn from a million peptides? Front Immunol. (2018) 9:1716.
doi: 10.3389/fimmu.2018.01716
83. Bhagwandin VJ, Bishop JM, Wright WE, Shay JW. The metastatic potential
and chemoresistance of human pancreatic cancer stem cells. PLoS ONE.
(2016) 11:e0148807. doi: 10.1371/journal.pone.0148807
84. Schmitz-Winnenthal FH, Volk C, Z’Graggen K, Galindo L, Nummer D,
Ziouta Y, et al. High frequencies of functional tumor-reactive T cells in
bone marrow and blood of pancreatic cancer patients. Cancer Res. (2005)
65:10079–87. doi: 10.1158/0008-5472.CAN-05-1098
85. Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin W-C, Mansour J, et al.
Whole-exome sequencing of pancreatic cancer defines genetic diversity and
therapeutic targets. Nat Commun. (2015) 6:6744. doi: 10.1038/ncomms7744
86. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Jöhnk C, et al.
Systemic and local immunosuppression in pancreatic cancer patients. Clin
Cancer Res. (2001) 7:925s−32s.
87. Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, Simon I, et al.
Control of T-cell–mediated immune response by HLA class I in human
pancreatic carcinoma. Clin Cancer Res. (2005) 11:498–504.
88. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of
cytotoxic chemotherapy: implications for the design of novel and rationale-
based combined treatments against cancer. Cell Death Differ. (2014) 21:15–
25. doi: 10.1038/cdd.2013.67
89. Burris, HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano
MR, et al. Improvements in survival and clinical benefit with gemcitabine as
first-line therapy for patients with advanced pancreas cancer: a randomized
trial. J Clin Oncol. (1997) 15:2403–13. doi: 10.1200/JCO.1997.15.6.2403
90. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al.
Adjuvant chemotherapy with gemcitabine vs observation in patients
undergoing curative-intent resection of pancreatic cancer: a randomized
controlled trial. JAMA. (2007) 297:267–77. doi: 10.1001/jama.297.3.267
91. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine
on immune cells in subjects with adenocarcinoma of the pancreas. Cancer
Immunol Immunother. (2005) 54:915–25. doi: 10.1007/s00262-004-0638-1
92. Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, et al.
Regular dose of gemcitabine induces an increase in CD14+ monocytes and
CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J
Clin Oncol. (2009) 39:797–806. doi: 10.1093/jjco/hyp112
93. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ,
et al. Induction of tumor cell apoptosis in vivo increases tumor
antigen cross-presentation, cross-priming rather than cross-tolerizing
host tumor-specific CD8T cells. J Immunol. (2003) 170:4905–13.
doi: 10.4049/jimmunol.170.10.4905
94. Miyazawa M, Katsuda M, Maguchi H, Katanuma A, Ishii H, Ozaka M, et al.
Phase II clinical trial using novel peptide cocktail vaccine as a postoperative
adjuvant treatment for surgically resected pancreatic cancer patients. Int J
Cancer. (2017) 140:973–82. doi: 10.1002/ijc.30510
95. Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, Higuchi H, et al.
Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell
vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci.
(2015) 106:397–406. doi: 10.1111/cas.12621
96. Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura
K, et al. Clinical and immunologic evaluation of dendritic cell-based
immunotherapy in combination with gemcitabine and/or S-1 in patients
with advanced pancreatic carcinoma. Pancreas. (2012) 41:195–205.
doi: 10.1097/MPA.0b013e31822398c6
97. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1
identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating
human tumors. J Clin Invest. (2014) 124:2246–59. doi: 10.1172/JCI
73639
98. Fu J, Malm I-J, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical
evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to
elicit regression of established tumors. Cancer Res. (2014) 74:4042–52.
doi: 10.1158/0008-5472.CAN-13-2685
99. Sierro SR, Donda A, Perret R, Guillaume P, Yagita H, Levy F, et al.
Combination of lentivector immunization and low-dose chemotherapy or
PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor
immunity. Eur J Immunol. (2011) 41:2217–28. doi: 10.1002/eji.201041235
100. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-
1/PD-L1 blockade together with vaccine therapy facilitates effector T-
cell infiltration into pancreatic tumors. J Immunother. (2015) 38:1–11.
doi: 10.1097/CJI.0000000000000062
101. Morse MA, Lyerly HK. Checkpoint blockade in combination with cancer
vaccines. Vaccine. (2015) 33:7377–85. doi: 10.1016/j.vaccine.2015.10.057
102. Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert
A, et al. Dendritic cell based tumor vaccination in prostate and renal cell
cancer: a systematic review and meta-analysis. PLoS ONE. (2011) 6:e18801.
doi: 10.1371/journal.pone.0018801
103. Boudewijns S, Westdorp H, Koornstra RHT, Aarntzen EHJG, Schreibelt
G, Creemers JHA, et al. Immune-related adverse events of dendritic
cell vaccination correlate with immunologic and clinical outcome in
stage III and IV melanoma patients. J Immunother. (2016) 39:241–8.
doi: 10.1097/CJI.0000000000000127
104. Nesselhut J, Marx D, Lange H, Regalo G, Cillien N, Chang RY, et al.
Systemic treatment with anti-PD-1 antibody nivolumab in combination with
vaccine therapy in advanced pancreatic cancer. J Clin Oncol. 2016 34:3092.
doi: 10.1200/JCO.2016.34.15_suppl.3092
105. Simon S, Labarriere N. PD-1 expression on tumor-specific T cells:
friend or foe for immunotherapy? Oncoimmunology. (2017) 7:e1364828.
doi: 10.1080/2162402X.2017.1364828
106. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW.
Effect of daily aspirin on long-term risk of death due to cancer: analysis of
individual patient data from randomised trials. Lancet. (2011) 377:31–41.
doi: 10.1016/S0140-6736(10)62110-1
107. Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R. Low-dose aspirin
and cancer mortality: a meta-analysis of randomized trials.Am JMed. (2012)
125:560–7. doi: 10.1016/j.amjmed.2012.01.017
108. Kalinski P. Regulation of immune responses by prostaglandin E(2). J
Immunol. (2012) 188:21–8. doi: 10.4049/jimmunol.1101029
109. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2
promotes tumor progression by inducing myeloid-derived suppressor cells.
Cancer Res. (2007) 67:4507–13. doi: 10.1158/0008-5472.CAN-06-4174
110. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc’h N, Zeng G, et al.
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell
function in human CD4+ T cells. J. Immunol. (2005) 175:1483–90.
doi: 10.4049/jimmunol.175.3.1483
111. Walker C, Kristensen F, Bettens F, deWeck AL. Lymphokine regulation
of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of
interleukin 2 production. J Immunol. (1983) 130:1770–3.
112. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T,
et al. Checkpoint blockade cancer immunotherapy targets tumour-specific
mutant antigens. Nature. (2014) 515:577–81. doi: 10.1038/nature13988
Frontiers in Immunology | www.frontiersin.org 16 August 2019 | Volume 10 | Article 1832
Bassani-Sternberg et al. Personalized Vaccine for Pancreatic Cancer
113. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca
S, et al. Predicting immunogenic tumour mutations by combining
mass spectrometry and exome sequencing. Nature. (2014) 515:572–6.
doi: 10.1038/nature14001
114. Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony
N, et al. Use of HLA peptidomics and whole exome sequencing to
identify human immunogenic neo-antigens. Oncotarget. (2016) 7:5110–7.
doi: 10.18632/oncotarget.6960
115. Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, et al.
Novel and shared neoantigen derived from histone 3 variant H3.3K27M
mutation for glioma T cell therapy. J Exp Med. (2018) 215:141–57.
doi: 10.1084/jem.20171046
116. Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B,
Swaminathan K, et al. Antigen presentation profiling reveals recognition
of lymphoma immunoglobulin neoantigens. Nature. (2017) 543:723–7.
doi: 10.1038/nature21433
117. Laumont CM, Daouda T, Laverdure JP, Bonneil E, Caron-Lizotte O, Hardy
MP, et al. Global proteogenomic analysis of human MHC class I-associated
peptides derived from non-canonical reading frames. Nat Commun. (2016)
7:10238. doi: 10.1038/ncomms10238
118. Laumont CM, Vincent K, Hesnard L, Audemard E, Bonneil E,
Laverdure JP, et al. Noncoding regions are the main source of
targetable tumor-specific antigens. Sci Transl Med. (2018) 10:aau5516.
doi: 10.1126/scitranslmed.aau5516
119. Andreatta M, Nielsen M. Gapped sequence alignment using
artificial neural networks: application to the MHC class I system.
Bioinformatics. (2015) 32:511–7. doi: 10.1093/bioinformatics/
btv639
120. Abelin JG, Keskin DB, Sarkizova S, Hartigan CR, Zhang W, Sidney J, et al.
Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic
cells enables more accurate epitope prediction. Immunity. (2017) 46:315–26.
doi: 10.1016/j.immuni.2017.02.007
121. Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-
4.0: improved peptide-MHC class I interaction predictions integrating eluted
ligand and peptide binding affinity data. J Immunol. (2017) 199:3360–8.
doi: 10.1101/149518
122. Pearson H, Daouda T, Granados DP, Durette C, Bonneil E, Courcelles M,
et al. MHC class I-associated peptides derive from selective regions of the
human genome. J Clin Invest. (2016) 126:4690–701. doi: 10.1172/JCI88590
123. Calis JJ, MaybenoM, Greenbaum JA,Weiskopf D, De Silva AD, Sette A, et al.
Properties of MHC class I presented peptides that enhance immunogenicity.
PLoS Comput Biol. (2013) 9:e1003266. doi: 10.1371/journal.pcbi.1003266
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Bassani-Sternberg, Digklia, Huber, Wagner, Sempoux, Stevenson,
Thierry, Michaux, Pak, Racle, Boudousquie, Balint, Coukos, Gfeller, Martin
Lluesma, Harari, Demartines and Kandalaft. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 17 August 2019 | Volume 10 | Article 1832
